Cell Host & MicrobeMicrobiologyPeer-reviewed journal article
Lineage-mosaic and mutation-patched spike proteins for broad-spectrum COVID-19 vaccine
Y. Wu, S. Wang, Y. Zhang, L. Yuan, Q. Zheng, M. Wei, Y. Shi, Z. WangiD, J. Ma, K. Wang, M. Nie, J. Xiao, Z. Huang, P. Chen, H. Guo, M. Lan, J. Xu, W. Hou, Y. Hong, D. Chen, H. Sun, H. Xiong, M. Zhou, C. Liu, W. Guo, , N. Xia
Abstract
The widespread SARS-CoV-2 in humans results in the continuous emergence of new variants. Recently emerged Omicron variant with multiple spike mutations sharply increases the risk of breakthrough infection or reinfection, highlighting the urgent need for new vaccines with broad-spectrum antigenic coverage. Using inter-lineage chimera and mutation patch strategies, we engineered a recombinant monomeric spike variant (STFK1628x), which showed high immunogenicity and mutually complementary antigenicity to its prototypic form (STFK). In hamsters, a bivalent vaccine comprised of STFK and STFK1628x elicited high titers of broad-spectrum antibodies to neutralize all 14 circulating SARS-CoV-2 variants, including Omicron; and fully protected vaccinees from intranasal SARS-CoV-2 challenges of either the ancestral strain or immune-evasive Beta variant. Strikingly, the vaccination of hamsters with the bivalent vaccine completely blocked the within-cage virus transmission to unvaccinated sentinels, for either the ancestral SARS-CoV-2 or Beta variant. Thus, our study provides new insights and antigen candidates for developing next-generation COVID-19 vaccines.
- organism: mouse
- assay: protein structure
- research focus: drug response / drug discovery
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Updated vaccine protects from infection with SARS-CoV-2 variants, prevents transmission and is immunogenic against Omicron in hamsters
S. Sharma, T. Vercruysse, … K. Dallmeier·bioRxiv·Nov 12, 2021
- Immunogenicity and efficacy of a subcutaneously administered, adjuvanted vaccine containing modified S1 spike protein of SARS-CoV-2 variant C.1.2
M. L. Bowe, E. M. Wright, … D. C. Wright·bioRxiv·Aug 31, 2023
- Striking Antibody Evasion Manifested by the Omicron Variant of SARS-CoV-2
L. Liu, S. Iketani, … D. D. Ho·bioRxiv·Dec 14, 2021
- Site of vulnerability on SARS-CoV-2 spike induces broadly protective antibody to antigenically distinct omicron SARS-CoV-2 subvariants
S. Changrob, P. J. Halfmann, … P. C. Wilson·bioRxiv·Oct 31, 2022
- Vaccination with B.1.1.7, B.1.351 and P.1 variants protects mice from challenge with wild type SARS-CoV-2
F. Amanat, S. Strohmeier, … F. Krammer·bioRxiv·Aug 5, 2021
- Construction of a potent pan-vaccine based on the evolutionary tendency of SARS-CoV-2 spike protein.